This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Andrew Butcher is speaking on “Balancing cost effectiveness with economics – alleviate funding constraints on HTA approved drugs by managing diverging stakeholder perspectives.” CRA is also sponsoring the conference.
For more information on the event, click here.
Insights from the MAPS New Orleans 2025 roundtable session. The session highlighted the essential talent needs—such as competencies, qualifications, and...
In the past three years, the Food and Drug Administration has approved around 50 drugs annually, including both new compounds and products similar to existing...
Abhishek Kumar presents his poster titled “Top Trends Affecting the Vaccines Market and their Implications on Access Policy and Public Health...
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
